These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18594815)

  • 1. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
    Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
    Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
    Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
    Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):260-9. PubMed ID: 19771426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of
    Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
    Ekblad T; Orlova A; Feldwisch J; Wennborg A; Karlström AE; Tolmachev V
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3912-4. PubMed ID: 19364646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
    Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
    Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
    Tran TA; Rosik D; Abrahmsén L; Sandström M; Sjöberg A; Wållberg H; Ahlgren S; Orlova A; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1864-73. PubMed ID: 19504093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
    Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
    Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.